CHPG|cas:170846-74-9|西域试剂

CHPG,99.0%

产品编号：Bellancom-101364| CAS NO：170846-74-9| 分子式：C₈H₈ClNO₃| 分子量：201.61

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-101364		￥3600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CHPG

产品介绍

CHPG 是一个选择性的 mGluR5 激动剂，并且通过 TSG-6/NF-κB 途径减弱 BV2 小神经胶质细胞 SO₂ 诱导的氧化应激和炎症。 CHPG 通过 ERK 和 Akt 途径在体外和体内预防创伤性脑损伤 (TBI)。

生物活性

CHPG is a selective mGluR5 agonist, and attenuates SO₂-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells. CHPG protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways.

体外研究

CHPG (10-500 µM; 24 hours) significantly increases the cell viability and decreases the LDH release after SO₂ derivatives treatment.
CHPG (0.5 mM; 30 mins ) protects BV2 cells against SO₂-induced apoptosis.
CHPG (0.5 mM; 30 mins) treatment alone increases the expression of TSG-6 in both mRNA and protein levels.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	BV2 microglial cells
Concentration:	10, 50, 100 and 500 µM
Incubation Time:	24 hours
Result:	Increased the cell viability.

Apoptosis Analysis

Cell Line:	BV2 microglial cells
Concentration:	0.5 mM
Incubation Time:	30 mins
Result:	Protected BV2 cells against SO₂-induced apoptosis.

Western Blot Analysis

Cell Line:	BV2 microglial cells
Concentration:	0.5 mM
Incubation Time:	30 mins
Result:	Increased the expression of TSG-6 in both mRNA and protein levels.

体内研究
(In Vivo)

CHPG (injection; 250 nM; for 7 days) reduces significantly cerebral lesion volume.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult Sprague-Dawley male rats weighing 280-320 g
Dosage:	250 nM
Administration:	Injection; for 7 days
Result:	Reduced significantly cerebral lesion volume.

体内研究

CHPG (injection; 250 nM; for 7 days) reduces significantly cerebral lesion volume.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult Sprague-Dawley male rats weighing 280-320 g
Dosage:	250 nM
Administration:	Injection; for 7 days
Result:	Reduced significantly cerebral lesion volume.

体内研究

CHPG (injection; 250 nM; for 7 days) reduces significantly cerebral lesion volume.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult Sprague-Dawley male rats weighing 280-320 g
Dosage:	250 nM
Administration:	Injection; for 7 days
Result:	Reduced significantly cerebral lesion volume.

性状

Solid

溶解性数据

In Vitro:

1M NaOH : 25 mg/mL (124.00 mM; ultrasonic and adjust pH to 11 with NaOH)

DMSO : < 1 mg/mL (ultrasonic) (insoluble or slightly soluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.9601 mL	24.8004 mL	49.6007 mL
5 mM	0.9920 mL	4.9601 mL	9.9201 mL
10 mM	0.4960 mL	2.4800 mL	4.9601 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式